Aviva plc Could Be Worth 660p!

Shares in Aviva plc (LON: AV) could rocket to 660p – here’s why.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a fantastic turnaround in recent years for Aviva (LSE: AV) (NYSE: AV.US), with its current management team successfully changing the operations of the business so as to deliver much-improved bottom line performance. In fact, shares in the company have risen by 14% in the last year alone and, looking ahead, a further 20% rise seems to be a very realistic target. Here’s why Aviva could make those gains and reach 660p per share.

Growth Potential

Although Aviva’s bottom line is forecast to increase by a rather lowly 4% this year, the insurer is expected to deliver much stronger gains in 2016. In fact, Aviva’s earnings are due to grow by 15% next year, which is a considerably higher rate of growth than the FTSE 100, and shows that Aviva’s current strategy of disposing of riskier and lower reward divisions is proving to be a successful one. And, with there being a considerable amount of rationalisation yet to come, Aviva could continue to surprise on the upside when it comes to its bottom line prospects for the medium to long term.

Valuation

Despite having the potential to grow profit at a much faster rate than the wider index, Aviva is still priced at a sizeable discount. For example, it has a price to earnings (P/E) ratio of just 11.1, while the FTSE 100’s P/E is much higher at around 16. As such, Aviva could see its share price trade at 660p through there being an upward rerating to its valuation that still leaves it trading at a discount to the wider sector.

For example, a P/E ratio of 13.5 would be sufficient for Aviva’s shares to trade at 660p, and yet this would still leave them at a sizeable discount to the FTSE 100’s P/E ratio. As such, a price target of 660p seems to be very achievable for Aviva over the medium term.

Looking Ahead

While Aviva’s share price will not move higher all on its own, there seems to be sufficient news flow in the pipeline to change investor sentiment sufficiently to push its rating higher. Notably, there is the merger with Friends Life that could cause investors to rethink their views on how Aviva can continue to generate upbeat earnings growth (i.e. through cost savings rather than purely through revenue growth), while the company’s rationalisation plans have yet to be fully completed, which may also mean further improvements in profitability moving forward.

Therefore, while the reaching of 660p would represent impressive performance over the medium term, Aviva is a stock with huge long term potential. As such, it seems to be well worth buying at the present time, with very appealing gains being on offer as the company continues to go from strength to strength.

Peter Stephens owns shares of Aviva and Friends Life. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Here’s how investors can aim for £11,363 a year in passive income from £20,000 in this overlooked FTSE media gem

I think this media stock is commonly overlooked by investors looking for high passive income, but it shouldn’t be, given…

Read more »

Tesla car at super charger station
Investing Articles

Why is Tesla stock down 30% since late 2025?

Tesla stock has been a bit of a car crash in 2026. Edward Sheldon looks at what’s going on, and…

Read more »

UK supporters with flag
Investing Articles

Is Wise now the UK stock market’s top growth share?

Wise rose around 4% in the UK stock market yesterday, bringing its four-year gain to 135%. Why are investors warming…

Read more »

Warhammer World gathering
Investing Articles

£20,000 invested in this FTSE 100 stock 10 years ago is now worth this astonishing amount…

This FTSE 100 stock's delivered an amazing return over the past 10 years. James Beard considers whether it’s worth holding…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

8.4%! Why do Legal & General shares always have such a high dividend yield?

Legal & General shares come with an 8.4% dividend yield. But this is essentially a risk premium for buying shares…

Read more »